Pentamedix Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
10
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.15M
Pentamedix General Information
Description
Developer of personalized anti-cancer vaccines designed for cancer treatment. The company creates a personalized anti-cancer vaccine that fundamentally blocks the immune evasion mechanism of cancer cells and enhances the immune response of T cells as an anti-cancer vaccine that targets neoantigens, enabling patients to raise the body's immune response to cancer.
Contact Information
Website
pentamedix.comCorporate Office
- Rooms 901-903, 912-913, Building B
- Pangyo Global Biz Center, 43 Changchang-ro, Sujeong-gu
- Seongnam, Gyeonggi 13449
- South Korea
Corporate Office
- Rooms 901-903, 912-913, Building B
- Pangyo Global Biz Center, 43 Changchang-ro, Sujeong-gu
- Seongnam, Gyeonggi 13449
- South Korea
Pentamedix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 11-Sep-2025 | $1.15M | Completed | Startup | ||
| 3. Early Stage VC (Series A) | 29-Mar-2020 | Completed | Startup | |||
| 2. Seed Round | 29-Aug-2019 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Jan-2019 | Completed | Startup |
Pentamedix Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pentamedix Patents
Pentamedix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023055122-A1 | Method and device for predicting treatment response to cancer immunotherapy by using neoantigen marker and global dna methylation marker | Inactive | 29-Sep-2021 | ||
| JP-2024533764-A | Method for predicting immune anti-cancer therapy response using dna methylation mutations of line-1 | Pending | 29-Sep-2021 | ||
| US-20240392385-A1 | Method for predicting response to cancer immunotherapy by using dna methylation aberration in line-1 | Pending | 29-Sep-2021 | ||
| WO-2023055128-A1 | Method for predicting response to cancer immunotherapy by using dna methylation aberration in line-1 | Inactive | 29-Sep-2021 | ||
| JP-2024513812-A | Method and analyzer for predicting t cell activity against peptide-mhc | Active | 30-Mar-2021 | G16B40/20 |
Pentamedix Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Pentamedix Former Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| InterVest | Venture Capital | Minority | ||
| Kite Entrepreneur Foundation | Accelerator/Incubator | Minority |
Pentamedix FAQs
-
When was Pentamedix founded?
Pentamedix was founded in 2019.
-
Where is Pentamedix headquartered?
Pentamedix is headquartered in Seongnam, South Korea.
-
What is the size of Pentamedix?
Pentamedix has 10 total employees.
-
What industry is Pentamedix in?
Pentamedix’s primary industry is Drug Discovery.
-
Is Pentamedix a private or public company?
Pentamedix is a Private company.
-
What is the current valuation of Pentamedix?
The current valuation of Pentamedix is .
-
What is Pentamedix’s current revenue?
The current revenue for Pentamedix is .
-
Who are Pentamedix’s investors?
InterVest and Kite Entrepreneur Foundation have invested in Pentamedix.
-
When was Pentamedix acquired?
Pentamedix was acquired on 11-Sep-2025.
-
Who acquired Pentamedix?
Pentamedix was acquired by SCL Science.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
